CAVHANZA vs TAGRISSO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. CAVHANZA and TAGRISSO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	CAVHANZA	TAGRISSO
Rating	New	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	NILOTINIB	OSIMERTINIB MESYLATE
Manufacturer	Flex Pharma	Astrazeneca
Dosage forms	Tablet, orally disintegrating	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors	Non-Small-Cell Lung Carcinoma

cavhanza tagrisso

Rating

New

70/100

Pharmacy pays

—

Type

Active ingredient

NILOTINIB

OSIMERTINIB MESYLATE

Manufacturer

Flex Pharma

Astrazeneca

Dosage forms

Tablet, orally disintegrating

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors

Non-Small-Cell Lung Carcinoma

Frequently asked questions

What is the difference between Cavhanza and Tagrisso?

Cavhanza contains Nilotinib, while Tagrisso contains Osimertinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.